Media Coverage
PharmaShots
Vergent BioScience’s VGT-309 shows promising potential for tumor visualization during lung cancer surgeries. VGT-309 is an investigational intraoperative molecular imaging (IMI) agent that utilizes near-infrared (NIR) fluorescence imaging to improve precision.
MedTech Gurus
Tell the Story in a Compelling Way
Welcome Med Tech Gurus, You are in for a treat In this episode we're honored to have Dr. John Santini, President & CEO of Vergent Bioscience, as our guest. Dr. Santini, recognized as one of Popular Science's "Brilliant Ten," shares his journey in driving innovation at Vergent Biosciences.
ONCOLife
The Promise of VGT-309 in Minimally Invasive Lung Cancer Surgery
The investigational tumor-targeted fluorescent imaging agent VGT-309 may enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time and help them ensure all tumor tissue is removed during surgery. In an exclusive interview with ONCOLife, Dr. John Santini, Chief Executive Officer & President at Vergent Bioscience, sheds light on VGT-309.
HospiMedica
Novel Fluorescent Imaging Agent Helps Surgeons Visualize Missed Lung Tumors
Surgery remains the primary treatment for most solid tumors, but conventional open surgery often results in significant trauma and high costs. Minimally invasive (MIS) and robotic-assisted surgical techniques have become increasingly popular as they reduce tissue damage, pain, blood loss, duration of hospital stays, and postoperative complications.
Windham Venture Partners
The Dye that Binds: Advances in Tumor Visualization Now Help Surgeons See Cancer in Real-Time
As surgical oncology moves toward increased adoption of minimally invasive techniques and procedures, the ability to locate and see tumors is vital. Once a surgeon loses the ability to visualize directly and use tactile sensation to identify and locate tumors, what can provide that needed layer of confidence?